Probiotic Intervention and Its Influence on Serum Leucine-Rich Alpha-2 Glycoprotein 1 Levels in Acne Vulgaris Patients

NCT07277075 | Completed

• 1 other identifier: 40-10-2024
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This study aimed to assess the serum level of Leucine-rich alpha-2 glycoprotein 1 (LRG1) in Acne vulgaris (AV) individuals and evaluate the effect of probiotic therapy on these serum levels.

Conditions

Probiotic; Influence; Acne Vulgaris; Serum Leucine-Rich Alpha-2 Glycoprotein 1

Outcome Measures

Primary Outcomes (1)

• Serum Leucine-Rich Alpha-2 Glycoprotein 1 Level

  Serum Leucine-Rich Alpha-2 Glycoprotein 1 Level was assessed.

  12 weeks after the therapy

Secondary Outcomes (2)

• Acne severity

  12 weeks after the therapy

• Patient satisfaction

  12 weeks after the therapy

Study Arms (2)

Study group

Participants with clinically diagnosed mild to moderate acne vulgaris (AV) based on the Glycosaminoglycans (GAGs).

Diagnostic Test: Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) level

Control group

Apparently healthy controls matched for age and sex

Diagnostic Test: Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) level

Interventions

Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) level DIAGNOSTIC_TEST

Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) levels were assessed in acne vulgaris participants and healthy controls.

Control group; Study group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This case-control study was conducted on all participants enrolled from the Dermatology \& Andrology Outpatient Clinic at Benha University Hospital, Egypt, between October 2024 and September 2025.

You may qualify if:

• Age ≥18 years.
• Both sexes.
• Had not used systemic or topical acne therapy for at least two months or two weeks before the research, respectively.
• Participants with clinically diagnosed mild to moderate acne vulgaris (AV) based on the Global Acne Grading System (GAGS)

You may not qualify if:

• Pregnancy.
• Lactation.
• History of hypersensitivity to probiotic components.
• Smoking.
• Presence of infections.
• Autoimmune or malignant diseases.
• Receiving any systemic therapy likely to affect the microbiome or inflammatory biomarkers.

Sponsors & Collaborators

• Benha University: lead

Study Sites (1)

Benha University

Banhā, Benha, 13518, Egypt

Location

MeSH Terms

Conditions

Acne Vulgaris

Condition Hierarchy (Ancestors)

Acneiform Eruptions; Skin Diseases; Skin and Connective Tissue Diseases; Sebaceous Gland Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MBBCH of Dermatology, Venereology and Andrology, Benha University, Benha, Egypt.

Study Record Dates

• First Submitted: November 29, 2025
• First Posted: December 11, 2025
• Study Start: October 1, 2024
• Primary Completion: September 30, 2025
• Study Completion: September 30, 2025
• Last Updated: December 11, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)